Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer

NCT01301911 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Cipatinib

Sponsor

Jiangsu HengRui Medicine Co., Ltd.

Collaborators

[object Object]